New hope for lung cancer: experimental drug combo targets resistant tumors
NCT ID NCT06928389
First seen Apr 10, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This phase 3 trial tests whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer whose disease has progressed after prior immunotherapy. About 536 adults will receive either ivonescimab or a placebo, both with docetaxel. The main goal is to see if the combination improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivonescimab and docetaxel
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease has worsened after standard immunotherapy.
What could go wrong
This is still an experimental approach; it may not improve survival or could cause more side effects than standard care. Results are not yet known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.